RECURSION PHARMACEUTICALS, INC. (RXRX) FY2026 YTD Q2 P&L / Income Statement

RECURSION PHARMACEUTICALS, INC. (RXRX) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

14,143,000 US dollars

Cost of revenue

23,981,000 US dollars

Gross profit (calculated)

negative 9,838,000 US dollars

Operating expenses (calculated)

253,634,000 US dollars

Loss from operations

negative 263,472,000 US dollars

Other income (loss), net

10,359,000 US dollars

Loss before income tax benefit

negative 253,113,000 US dollars

Income tax benefit

negative 4,604,000 US dollars

Net loss

negative 248,509,000 US dollars

Operating revenue

13,605,000 US dollars

Grant revenue

538,000 US dollars

Research and development

177,510,000 US dollars

General and administrative

76,124,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.